The ability of 2-deoxyglucose to promote the lysis of Streptococcus bovis JB1 via a mechanism involving cell wall stability.
The non-metabolizable glucose analog, 2-deoxyglucose (2-DG), decreased the growth rate and optical density of Streptococcus bovis JB1 20%, but it had an even greater effect on stationary phase cultures. Control cultures receiving only glucose (2 mg/ml) lysed very slowly (<5% decline in optical density in 48 h), but cultures that had been grown with glucose and 2-DG (2 mg/ml each) lysed much faster (>85% decline in optical density in 48 h). Cultures that were treated with inhibitors that decreased intracellular ATP (sodium fluoride, nigericin, and valinomycin or tetrachlorosalicylanilide) or membrane potential (sodium fluoride, nigericin, and valinomycin, tetrachlorosalicylanilide, or phenylmethylsulfonyl fluoride) did not promote lysis. 2-DG had its greatest effect when it was added at inoculation. If 2-DG was added at later times, less lysis was observed, and cells that were given 2-DG just prior to stationary phase were unaffected. Cells that were grown with glucose and 2-DG were more susceptible to cell wall-degrading enzymes (lysozyme and mutanolysin) than cells that had been grown only with glucose, but sublethal doses of penicillin during growth did not promote lysis after the cells had reached stationary phase. The idea that 2-DG might be affecting autolytic activity was supported by the observation that cultures washed and resuspended in fresh medium with or without 2-DG lysed at a slower rate than cultures that were not centrifuged or were resuspended in the culture supernatant.
Russell
J B
JB
Agricultural Research Service, USDA, Ithaca, NY 14853, USA.
Wells
J E
JE
D000255:Adenosine Triphosphate / Q000378:metabolism; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000963:Antimetabolites / Q000494:pharmacology*; D001433:Bacteriolysis / Q000187:drug effects*; D002473:Cell Wall / Q000187:drug effects* / Q000378:metabolism; D003847:Deoxyglucose / Q000494:pharmacology*; D010450:Endopeptidases / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism / Q000494:pharmacology; D008564:Membrane Potentials; D009113:Muramidase / Q000494:pharmacology; D009550:Nigericin / Q000494:pharmacology; D010400:Penicillin G / Q000494:pharmacology; D010406:Penicillins / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D016196:S Phase / Q000187:drug effects; D012458:Salicylanilides / Q000494:pharmacology; D012969:Sodium Fluoride / Q000494:pharmacology; D016985:Streptococcus bovis / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D014105:Tosyl Compounds / Q000494:pharmacology; D014634:Valinomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000963:Antimetabolites; D004791:Enzyme Inhibitors; D010406:Penicillins; D011480:Protease Inhibitors; D012458:Salicylanilides; D014105:Tosyl Compounds; D014634:Valinomycin; C003614:4-toluenesulfonyl fluoride; D000255:Adenosine Triphosphate; D012969:Sodium Fluoride; D003847:Deoxyglucose; D009113:Muramidase; D010450:Endopeptidases; C021816:mutanolysin; C003390:3,3',4',5-tetrachlorosalicylanilide; D005947:Glucose; D010400:Penicillin G; D009550:Nigericin